Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 21;21(15):4744-9.
doi: 10.3748/wjg.v21.i15.4744.

Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis

Wen-Song Ge  1 , Jian-Gao Fan  1
Affiliations
Review

Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis

Wen-Song Ge et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in Crohn's disease (CD).

Methods: We carried out a literature search in PubMed, MEDLINE, EMBASE and the Cochrane Library to screen for citations from January 1990 to August 2014. Data analysis was performed using Review Manager version 5.2.

Results: A total of 1340 patients from five studies were involved in this meta-analysis. During 6-12 wk treatment, integrin antagonists increased the rate of clinical response and remission with OR = 1.69, 95%CI: 1.37-2.09 and 1.84, 95%CI: 1.44-2.34, respectively. No significant difference was found between integrin antagonists and placebo treatments regarding their adverse reactions (OR = 1.07, 95%CI: 0.83-1.38) and serious adverse reactions (OR = 0.81, 95%CI: 0.57-1.15).

Conclusion: The results prove the efficacy and safety of integrin antagonists for CD treatment, although the treatment strategies varied.

Keywords: Crohn’s disease; Drug efficacy; Drug safety; Integrin antagonist; Meta-analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the studies identified.
Figure 2
Figure 2
Forest plots of clinical response. Clinical response was defined as a decrement of ≥ 70 points in CDAI score from baseline (week 0). Ghosh 20031: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 20032: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 20033: 3 mg/kg natalizumab at 0 wk. Feagan 20081: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 20082: 0.5 mg/kg vedolizumab at 0 and 4 wk.
Figure 3
Figure 3
Forest plots of clinical remission. Clinical remission was defined as CDAI score < 150. Ghosh 20031: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 20032: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 20033: 3 mg/kg natalizumab at 0 wk. Feagan 20081: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 20082: 0.5 mg/kg vedolizumab at 0 and 4 wk.
Figure 4
Figure 4
Forest plots of common adverse reactions. Ghosh 20031: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 20032: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 20033: 3 mg/kg natalizumab at 0 wk. Feagan 20081: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 20082: 0.5 mg/kg vedolizumab at 0 and 4 wk.
Figure 5
Figure 5
Forest plots of serious adverse reactions. Ghosh 20031: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 20032: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 20033: 3 mg/kg natalizumab at 0 wk. Feagan 20081: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 20082: 0.5 mg/kg vedolizumab at 0 and 4 wk.
See this image and copyright information in PMC

References

    1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605. - PubMed
    1. Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. Gastroenterol Nurs. 2009;32:327–339. - PubMed
    1. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:160–170. - PubMed
    1. De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects? Dig Dis. 2012;30:368–375. - PubMed
    1. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630. - PubMed

MeSH terms